Beta-Blocker Initiation Post-ACS
Oral beta-blockers should be started within the first 24 hours after acute coronary syndrome in hemodynamically stable patients without contraindications, with careful avoidance of intravenous administration in those at risk for cardiogenic shock. 1
Timing and Route of Administration
Start oral beta-blockers early (within 24 hours) in patients presenting with ACS who meet stability criteria. The evidence strongly supports oral initiation over intravenous administration in most cases 2, 1. The COMMIT trial of 45,852 patients demonstrated that early high-dose intravenous metoprolol increased cardiogenic shock risk, particularly on day 1, despite reducing reinfarction and ventricular fibrillation 3, 4. This harm occurred predominantly in hemodynamically compromised patients.
Intravenous beta-blockers may be reasonable only in specific situations: severe hypertension or ongoing tachyarrhythmias in stable patients without shock risk factors 5, 2.
Hemodynamic Criteria for Safe Initiation
Do not initiate beta-blockers if any of the following are present:
- Signs of heart failure (Killip class II-IV) or pulmonary edema 2, 1
- Evidence of low cardiac output state or active cardiogenic shock 2
- Systolic blood pressure <100 mm Hg 4, 2
- Heart rate <60 bpm 2
- Systolic BP <120 mm Hg with heart rate >110 bpm (high shock risk) 6
Additional shock risk factors include: age >70 years, female sex, higher Killip class, time delay from symptom onset, and previous hypertension 3, 4. Patients with these characteristics experienced the greatest harm from early aggressive beta-blockade in COMMIT.
Absolute Contraindications
Do not administer beta-blockers if:
- PR interval >0.24 seconds (marked first-degree AV block) 3, 2, 1
- Second- or third-degree heart block without pacemaker 2, 1
- Active bronchospasm or severe reactive airway disease 2
- Severe bradycardia (<50 bpm) 5
Practical Initiation Strategy
For stable patients meeting criteria:
Start with low-dose oral beta-blocker and titrate gradually as blood pressure and heart rate permit 1. Preferred agents include:
- Metoprolol: 25-50 mg every 6 hours initially, titrate to 100 mg twice daily 4
- Carvedilol: 6.25 mg twice daily, uptitrate to maximum 25 mg twice daily 3, 4
- Bisoprolol: 10 mg daily 4
Use beta-1 selective agents without intrinsic sympathomimetic activity 3, 4.
Duration of Therapy
Continue beta-blockers for at least 3 years in patients with normal left ventricular function post-ACS 7. Continue indefinitely in patients with:
The most recent 2025 BETAMI-DANBLOCK trial (5,574 patients, median 3.5-year follow-up) demonstrated that beta-blockers reduced the composite endpoint of death or major adverse cardiovascular events (14.2% vs 16.3%, HR 0.85) in patients with EF ≥40%, primarily driven by reduced reinfarction (5.0% vs 6.7%, HR 0.73) 9. This supports continued use beyond the acute phase.
Common Pitfalls to Avoid
Do not use intravenous beta-blockers routinely in the first 24 hours—this increases cardiogenic shock risk without mortality benefit 3, 4, 2.
Reassess patients with initial contraindications after 24 hours for subsequent eligibility 6, 1. Many contraindications resolve with stabilization.
Do not withhold beta-blockers solely based on reactive airway disease history—this is a relative contraindication. Careful assessment of severity is needed, as beta-blockers reduced in-hospital mortality even in patients with reactive airway disease (OR 0.52) 10.
Monitor closely during titration for hypotension, bradycardia, heart failure symptoms, and bronchospasm 4.